CoRegen, Inc. Names Sonja Nelson Chief Financial Officer And Peter Gelinas Chief Technical Officer To Bolster Leadership

CoRegen, Inc., a biopharmaceutical company focused on developing innovative treatments for some of the most aggressive cancers, has announced the appointment of Sonja Nelson as Chief Financial Officer (CFO) and Peter Gelinas as Chief Technical Officer (CTO). These leadership additions are intended to strengthen CoRegen’s mission to pioneer next-generation therapies aimed at eliminating cancer and transforming modern cancer care.

Suneet Varma, Chairman of the Board at CoRegen, welcomed the new executives, noting that Nelson’s extensive financial expertise will support the company’s strategic growth, while Gelinas’ technical and operational experience will guide critical development processes. Gelinas’ background includes leading technical operations and meeting Investigational New Drug (IND)-enabling Chemistry, Manufacturing, and Controls (CMC) requirements for cell and gene therapies. 

Varma also expressed gratitude to John Thomas, who has been managing CFO responsibilities to date and providing steady leadership to keep the company on track toward its mission. Varma confirmed that CoRegen remains on course to move its lead solid-tumor candidate into a Phase 1/2 clinical trial in the first half of 2026.

Nelson expressed enthusiasm about joining CoRegen, highlighting the company’s innovative science and potential to reshape cancer treatment worldwide. She emphasized her commitment to helping shape the company’s strategic direction during this critical stage of growth. Gelinas shared his excitement about becoming part of CoRegen’s leadership team, praising the company’s scientists and vision. 

He stated that he looks forward to applying his technical, operational, and regulatory expertise to advance CoRegen’s transformative cancer therapies efficiently and at scale, ensuring they reach patients who need them most. These appointments mark an important step for CoRegen as it strengthens its leadership team to support the advancement of its oncology pipeline and prepare for key clinical milestones in the coming years.